Thomas Lynch
Yale, CONNE, United States
- This delegate is contactable by email.
- This delegate is presenting an abstract at this event.
Thomas J. Lynch, Jr., MD began his tenure as Director of Yale Cancer Center and Physician-in-Chief of Smilow Cancer Hospital at Yale-New Haven on April 1, 2009. The Jonathan and Richard Sackler Professor of Medicine, Dr. Lynch is an expert in the treatment of lung cancer with a special interest in personalized medicine.
A member of the Board of Directors for Bristol-Myers Squibb Company, Dr. Lynch is internationally known for his leadership in the development of novel therapies for the treatment of lung cancer. Using the molecular profile of lung tumors, he and his research team have developed methods to predict a tumor’s response to targeted drugs based on confirmed mutations in the epidermal growth factor receptor gene. The resulting information enables oncologists to create treatment plans that more effectively target each patient’s specific tumor type. This kind of customized care, often referred to as personalized medicine, is a standard of practice at Yale Cancer Center and Smilow Cancer Hospital at Yale-New Haven.
Dr. Lynch is the Chair of the Board of Directors and a founding member of the nationally recognized Kenneth B. Schwartz Center, named after a former patient of his. Currently in 39 states and at over 320 different sites, the Schwartz Center Rounds are multidisciplinary rounds focused on the connection between patients and caregivers to promote compassionate care. The Rounds were brought to Yale Cancer Center in 2007 and continue under Dr. Lynch’s leadership.
Prior to joining Yale, Dr. Lynch served as Professor of Medicine at Harvard Medical School and Chief of Hematology/Oncology at Massachusetts General Hospital (MGH) Cancer Center. Dr. Lynch received his undergraduate degree from Yale College in 1982 and his MD degree from Yale School of Medicine in 1986. He completed his internship and residency at MGH, and after serving a fellowship in medical oncology at the Dana-Farber Cancer Institute he joined the medical staff at the Massachusetts General Hospital in 1993. Dr. Lynch has published over 100 original scientific papers and authored or co-authored over 90 review articles and book chapters.
Presentations this author is a contributor to:
Novel approaches to NSCLC 2015: COSA 2014 annual meeting (#46)
4:00 PM
Thomas Lynch
Concurrent session - Metastases/recurrence
Targeted therapy for NSCLC 2015: second gen, third gen and beyond (#70)
9:10 AM
Thomas Lynch
Plenary - Recent improvements in lung cancer care; what you must know